INDIANAPOLIS / Aug 12, 2024 / Business Wire / The Whole Health Index (WHI), created by Elevance Health, Inc. (NYSE: ELV) physicians, data scientists, and researchers, is a first-of-its-kind assessment of health. Using a scale of 0 to 100, the WHI can evaluate a person or group’s relative health over time and assess the physical, behavioral, and social factors that influence it.
“Understanding a person’s overall health enables tailored solutions that drive positive health outcomes,” said Shantanu Agrawal, MD, Elevance Health Chief Health Officer. “We created the Whole Health Index to help assess health holistically, looking at its most powerful drivers. By establishing a credible measurement of individual and community health, we can inform programs and services that advance greater health and health equity.”
The WHI uses more than 90 data points that fall into broad categories of physical, behavioral, and social health. These data points range from food insecurity, transportation accessibility, and housing instability to preventative dental exams, immunizations, and treatment for mental health outcomes. Learn more about the WHI methodology.
Elevance Health recently provided access to WHI data from a subset of employer health plan members starting with two states, Missouri and Virginia. WHI data is accessible at the county level and always de-identified.
About Elevance Health, Inc.
Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve over 113 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.
Last Trade: | US$393.36 |
Daily Change: | 8.71 2.26 |
Daily Volume: | 2,528,181 |
Market Cap: | US$91.230B |
April 22, 2025 January 23, 2025 October 17, 2024 July 17, 2024 April 18, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load